Glucosuria
Biomarker1 paper4 findings
- Humans1
Interventions
1SGLT2 inhibitors
upin humans1OR 18.1Moderate certainty
1 study
SGLT2 inhibitors
upin humans1OR 18.1Moderate certainty
SGLT2 inhibitors increase glucosuria in humans (OR 18.1 (95% CI, 16.4-20.0)).
Humansin patients prescribed SGLT2 inhibitors
Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice · Journal of the American Society of Nephrology : JASN · 17 Sep 2026
Associations
3End-stage kidney disease
downin humans1HR 0.73
1 study
End-stage kidney disease
downin humans1HR 0.73
Glucosuria lowers the risk of end-stage kidney disease in humans (HR 0.73 (95% CI, 0.58-0.91)).
Humansin patients prescribed SGLT2 inhibitorsmean 3.3 years
Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice · Journal of the American Society of Nephrology : JASN · 17 Sep 2026
Heart failure hospitalization
downin humans1HR 0.87
1 study
Heart failure hospitalization
downin humans1HR 0.87
Glucosuria lowers the risk of heart failure hospitalization in humans (HR 0.87 (95% CI, 0.78-0.98)).
Humansin patients prescribed SGLT2 inhibitorsmean 3.3 years
Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice · Journal of the American Society of Nephrology : JASN · 17 Sep 2026
Mortality
downin humans1HR 0.78
1 study
Mortality
downin humans1HR 0.78
Glucosuria lowers the risk of mortality in humans (HR 0.78 (95% CI, 0.73-0.83)).
Humansin patients prescribed SGLT2 inhibitorsmean 3.3 years
Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice · Journal of the American Society of Nephrology : JASN · 17 Sep 2026